Key clinical point: Clinical and imaging outcomes improve among patients with MS who switch from interferon beta-1a to alemtuzumab.
Major finding: The rate of freedom from relapse ranged from 83% to 90%, and disability scores were stable for 51% of patients.
Study details: An examination of data for 117 patients with MS who participated in extensions of the CARE-MS II trial.
Disclosures: Sanofi and Bayer HealthCare Pharmaceuticals supported this study. Dr. Ionete received research support from Biogen, Roche, and Sanofi. She reported receiving compensation for advisory board participation from Sanofi.
REPORTING FROM CMSC 2019